A Phase 1 Randomized, Placebo-controlled, Double-blind Dose-escalation Trial to Evaluate the Safety and Immunogenicity of tgAAC09, a Gag-PR-RT AAV HIV Vaccine.
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2013
At a glance
- Drugs TgAAC 09 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 26 Jul 2007 New trial record.